JanOne Inc (JAN)

[Principian]

I read the SEC Complaint.

https://www.sec.gov/litigation/complaints/2021/comp25155.pdf

I am not surprised at all on this. This actually sheds lot of light on a number of things. When this is over Jon Issac and that CFO will both be Barred for Life from running any Public Company. One thing is for sure and is a big RedFlag when I started watching ARCI waste fact ARCI had an "Incestuous" Board of Directors with LIVE. Especially, the CFO being in charge of dealing with both sets of "Books". Shady People all the way around.

[Principian]

On Geotraq, everything about that Cellular Module (g200) Gregg Sullivan touted was a pure fraud. I have come across a few pathological liars in my life and one thing Gregg did when we first were in contactv via phone and zoom, he became super defensive and downright abusive when he was asked very "simple" telecom questions. He liked to represent himself as this unwitting genius that discovered a lot of things all on his own and that he knew how things worked.

I found it interesting that as I explained some things on true telecom systems worked, a few calls later he is telling me the exact things I educated him on, yet he tried to make it like I was a dumb ass and he was this glorious genius.

Back in late 2019, I was glad to see that ARCI fired him. I'd filed my FCC Complaint against him and Geotraq in the fall of 2019 for Activating those Modules without FCC Approvals. I also had spoken with a CEO that got hoodwinked into taking some of those unauthorized devices onto an airplane and had them active on his flights.

In the telecom industry, he rightfully would have been fired for Negligence and rightfully so. I am still absorbing this "Settlement".

[Principian]

That IP valuation was insane and still is. As part of this settlement it looks like Gregg has to forfeit those ARCI "Preferred Shares".

That Patent is still a major sticking point with me being a 35+ Telecom R&D Professional. Even though it was Granted, it is worthless. It was garbage from the very start. I had some hopes Pierre Parent being a long time telecom professional would have turned this thing around. I know he jumped ship back in 2019. So I was totally glad, I didn't go down the road to use geotraq on a cool national project of mine.

I still am a bit sad too, because I know a number of the Geotraq employees were harmed in this whole shitshow.

As far as that IP valuation, I will look at their latest Financials. They were writing off about $1Million a quarter from the balance sheet in relation to Geotraq.

And Gregg misrepresented the Capital Structure of Geotraq when we began talking back in 2017. That hasalways concerned me. Once I investigated the ARCI "Deal". The main component of this is what CEO in their "Right Mind" would ever have structured this deal as was done.

One other individual in this is Juan Yunis and last I checked he still had like 75% of those Preferred Shares from this whole deal. These Shares basically gave away the farm so to speak.

[againstallodds]

IP crazy valuation came back to bite JAN...

What’s funny is that we know it’s worth squat

[Principian]

Holy shit, so Gregg is ending up with about $2 million in payments. This is an insane world we live in... just read the settlement

Unreal...

[DJ Ponder]

Lmao....rotsa ruck collecting sullivan - the swamp rat.

[againstallodds]

Tony Isaac was removed as CEO

[againstallodds]

Sullivan countersued, was awarded $1,950K

https://sec.report/Document/0000950170-21-001461/jan-20210703ex10_2.htm

We are the subject of an SEC Complaint, which could divert management's focus, result in substantial litigation expenses and have an adverse impact on our business, reputation, financial condition, results of operations or stock price.

We are currently subject to an SEC Complaint. Refer to Note 15 to our Consolidated Financial Statements and Part II, Item 1 of this Quarterly Report for additional information regarding this specific matter. We may be subject to additional investigations, arbitration proceedings, audits, regulatory inquiries and similar actions, including matters related to intellectual property, employment, securities laws, disclosures, tax, accounting, class action and product liability, as well as regulatory and other claims related to our business and our industry, which we refer to collectively as legal proceedings. We cannot predict the outcome of any particular proceeding, or whether ongoing investigations, will be resolved favorably or ultimately result in charges or material damages, fines or other penalties, enforcement actions, bars against serving as an officer or director, or practicing before the SEC, or civil or criminal proceedings against us or members of our senior management.

Legal proceedings in general, and securities and class action litigation and regulatory investigations in particular, can be expensive and disruptive. Our insurance may not cover all claims that may be asserted against us, and we are unable to predict how long the legal proceedings to which we are currently subject will continue. An unfavorable outcome of any legal proceeding may have an adverse impact on our business, financial condition and results of operations or our stock price. Any proceeding could negatively impact our reputation among our stakeholders. Furthermore, publicity surrounding ongoing legal proceedings, even if resolved favorably for us, could result in additional legal proceedings against us, as well as damage our image.

[Principian]

Not kept up as much as I should. I was contacted over a year ago by a lawyer that was building a case against Gregg Sullivan concerning his actions that have harmed prior investors in Geotraq and I also was contacted by Jon Issac concerning my FCC Complaint against Geotraq for activating unauthorized devices. Jon and I spoke over the phone on a civil case going down against Gregg in Las Vegas. I will have to see where that case stands. As far as Geotraq goes, even Pierre Parent jumped ship.

If you have any links to any SEC Actions, share them.

My last analysis of of JanOne Financials, I had seen a note the "Recycling" was going to be sold off to the CFO and some Consortium he has put together.

On a Balance Sheet, they were in my opinion inflating the balance sheet with Geotraq. Not kept up on them moving into the Biotechnology Industry.

There have been numerous "Red Flags" the past several years concerning ARCI, Geotraq and now JanOne. I am just glad, I was smart enough not to move forward with Geotraq on one of my own projects in Telecom. Simple, Due Diligence always pays off. It cuts through the Hype and BS.

[againstallodds]

SEC after Janone, Tony and friends ... NO SURPRISE

[cheynew]

JANONE SELECTS CPC CLINICAL RESEARCH AS TRIAL MANAGER FOR PHASE 2B STUDY OF JAN101 FOR PERIPHERAL ARTERY DISEASE PATIENTS

CPC to Manage Planning, Organization, and Day-to-Day Execution of the Trial

PR Newswire
LAS VEGAS , July 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service academic research organization (ARO), as manager for its upcoming Phase 2b clinical trial of lead product candidate JAN101 for treating Peripheral Artery Disease (PAD). CPC will be responsible for the planning, organization, day-to-day execution, and management of the Company's study, and will collaborate with JanOne's appointed regulatory partner Avania , announced last month.

JanOne (PRNewsfoto/JanOne)
CPC is an ARO recognized for its expertise in comprehensive clinical trial design and management for both national and international clinical research. CPC has over 30 years of experience in managing Phase 1 to 4 clinical trials and has provided services for over 150 clinical studies. CPC is led by Marc Bonaca , MD, MPH, a renowned cardiologist and vascular medicine specialist, who has worked on numerous PAD clinical trials.

"CPC has an outstanding reputation for clinical trial management and we are thrilled to have their team on board for our upcoming Phase 2b trial," said Tony Isaac , President and Chief Executive Officer of JanOne. "CPC executes with the highest standards of excellence, and their oversight puts our study in the best possible position for scientific success and integrity."

Dr. Bonaca, Executive Director of CPC Clinical Research, commented, "A dominant morbidity in PAD is functional decline related to altered energetics and pain. Finding effective therapies to improve symptoms and lessen this morbidity has been challenging with few effective therapies available to patients. We believe that the mechanism of action of JAN101 holds promise for improving symptoms and function in symptomatic PAD and may offer a new avenue of treatment to patients and the medical community."

JanOne's pivotal Phase 2b study of JAN101 for PAD will evaluate the efficacy of two doses (40 and 80 mg) of JAN101 to treat diabetic patients with PAD in a placebo-controlled 6-month study. Plans are to study 300 diabetic adults with PAD in 3 cohorts of 100 patients each. The primary endpoint will be the ability of patients to walk without pain or muscle fatigue as a result of vascular function restored by JAN101. The secondary endpoints will be reduction in pain over the course of treatment, improved blood flow into the affected muscle, and improved quality of life.

About JanOne

JanOne (Nasdaq: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate, JAN101, is for potentially treating peripheral artery disease ("PAD"), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial and the Company is currently in preparations for Phase 2b trials. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions, and neuropathic pain. For more information, visit www.janone.com .

Forward-Looking and Cautionary Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, including those relating to the upcoming Phase 2b clinical trial of lead product JAN101 for treating peripheral artery disease. These forward-looking statements can be identified by terminology such as "will," "aims," "upcoming," "may," "expects," "expected," "potential," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. JanOne may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") on Forms 10-K and 10-Q, Current Reports on Form 8-K, in its annual report to stockholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report on Form 10-K for the fiscal year ended January 2, 2021 and other SEC filings (available at http://www.sec.gov ). JanOne undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Investor Relations & Media Contact
[e-mail]
1 [phone]

[TheFinalCD]

JAN NEWS HALT https://ir.janone.com/news-events/press-releases/detail/34/janone-advances-toward-initiation-of-phase-2b-peripheral

[Jess070283]

In on this dip!$$$

[Pedro2004]

I almost bought in at $7.00 -- glad I didn't. Someone dumped big-time for profits. Can't blame them, though.

[dinogreeves]

Nice work.

[crudeoil24]

I sold 17K @ 8.98

[dinogreeves]

Yes super low float waiting on to get filled at 7.85 now for 20 thousand shares.

[crudeoil24]

JAN101 > lead candidate.

[crudeoil24]

JanOne (NASDAQ:JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives. For more information, visit janone.com

[crudeoil24]

All time highs in AH. Super low floater.

[dinogreeves]

Maybe it will run huge next week in Jan

[TheFinalCD]

Jan in Jan would have been c00ler

[dinogreeves]

lol

[TheFinalCD]

Jan in Dec

[dinogreeves]

Yes ALP*P went crazy, had 618,000 shares sold 70-90 cents. Too early

[TheFinalCD]

#MARKET MANIPULATION

the market is running wild with it


Hedge Funds are even playing in the OTC

the biggest run ive ever seen is alpp

yesterday was uuu acy

today its $JAN


.0001- $4.79

[dinogreeves]

I got a small 2500 position and just placed an order for 20,000 shares at 7.75.

[dinogreeves]

No news, just a low market cap, should run to its appropriate valuation of 50 million market cap.

[TheFinalCD]

any news on this 1milly floater? https://www.finviz.com/quote.ashx?t=jan

[dinogreeves]

JAN will reach 50 dollars tomorrow market cap is way too small for this biotech.

[TFMG]

$JAN | #JanOne Is Our Low-Float Nasdaq Listed Biotech Alert








JanOne Inc. (NASDAQ: JAN)
Alert Price: $7.63
Float: 1.38M
Please turn your immediate attention to JanOne Inc. (NASDAQ: JAN).

JAN could be the next pharma stock to take Wall St . by storm.

The company is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. As a result, they hope to reduce the need for prescribing dangerous opioid drugs. Their first drug candidate (JAN101) is a treatment for Peripheral Arterial Disease (PAD), a condition that can cause severe pain and affects over 8.5 million people in the US alone.

The Company recently announced some exciting developments that could serve as a catalyst towards bringing its share price to levels not yet seen.

JAN has completed its initial engineering batch of JAN101. The JAN101 formulation is a patented sodium nitrite proprietary compound that demonstrated success in Phase 1 and Phase 2a trials for improving blood flow and vascular function, necessary in the treatment of Peripheral Artery Disease (PAD) and potentially for the treatment of Covid-19 vascular complications that is believed to be the cause of severe vital organ and tissue damage.

JAN has received authorization from the Food and Drug Administration (FDA) for the investigational new drug (IND) sponsorship transfer covering its sodium nitrite tablets and is currently preparing an investigator-initiated IND package for FDA submission, which it expects to submit in the coming weeks, as a potential treatment for certain aspects of bodily damage created by COVID-19. A pivotal phase 2b study for PAD is planned for early 2021.

The Bullish Case for JanOne (NASDAQ: JAN)

Has a razor thin float
A history of monster single day moves
Has tremendous upside
Trading well under book value of $8.71
52.97% Insider ownership
Expects to submit the investigational new drug (IND) for the treatment of Covid-19 vascular complications in the coming weeks and continues to advance plans to scale-up production of JAN101.
This is one of the most exciting opportunities we've seen in quite some time, we suggest that you act now, and add JAN to the top of your watchlist.

About JanOne

JanOne (NASDAQ: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names which are undergoing review to determine appropriate strategic alternatives. For more information, visit janone.com

Key Growth Drivers

Product Candidate: JanOne acquired an exclusive license to the worldwide right to TV1001SR, now known as JAN101, a twice-daily, orally dosed slow-release formulation. Over $13.5 million1 has been spent on the development in research and clinical work, excluding patent and Intellectual property expenses. Sodium nitrite is an approved drug for acute use and is on the list of The World Health Organizations list of 100 essential medications. Results from Phase 2a clinical trials support the use of sodium nitrite for the treatment and prevention of PAD and as a non-addictive treatment for Diabetic Neuropathy. While not a predetermined endpoint for the trial, subjects who participated in the trial also reported a reduction in pain as a result of the increased blood flow to the extremities and prompted a clinical study into diabetic pain where patients reported a significant reduction in pain.

Market Opportunity: In 2017, the global market for PAD was estimated at nearly $36.1 billion and is expected to grow at a compound annual growth rate ( CAGR ) of 7.6% to $52.0 billion by 2022, according to BCC Research.2

Patent Portfolio: The company has a portfolio of 30 worldwide patents and other intellectual property relating to sodium nitrite, the sustained release of sodium nitrite, and a provisional application to assist in the treatment of COVID-19 vascular complications. The patent portfolio presents diverse licensing opportunities and potentially royalty opportunities if JanOne intellectual property is used with other drug candidates.

Manufacturing underway: The company has a manufacturing agreement with CoreRx Inc. for the formulation and manufacturing of JAN101. CoreRx operates over 150,000 square feet of cGMP lab and manufacturing facilities, including six formulation suites, 18 manufacturing suites, and two analytical labs.

FDA 505 (b)(2) pathway: To streamline development and approval of the U.S. Food and Drug Administration (the “FDA”), the company expects to pursue FDA 505(b)(2) pathway for new drug approval as a result of an already approved acute use associated with JAN101.

Recent Highlights

In July 2020, several esteemed colleagues joined JanOne's Scientific Advisory Board
In July 2020, JanOne received confirmation from the FDA for the investigational new drug (IND) sponsorship transfer covering its sodium nitrite tablets previously held by Soin Neuroscience
In August 2020, JanOne engages CATO-SMS a world leading clinical research organization to assist in the development of JAN101 to Treat COVID-19 Vascular Complications
In August 2020, JanOne completes stable formulation of JAN101 in preparation for its first GMP manufacturing batch to support upcoming clinical trials
JAN Working Towards Treatment Of Covid-19

JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness

Engineering batch for JAN101 complete and expectations are for GMP batch production to begin within 30 days

JAN has successfully completed its initial engineering batch of JAN101. The JAN101 formulation is a patented sodium nitrite proprietary compound that demonstrated success in Phase 1 and Phase 2a trials for improving blood flow and vascular function, necessary in the treatment of Peripheral Artery Disease (PAD) and potentially for Covid-19 vascular complications that is believed to be the cause of severe vital organ and tissue damage.

According to Dr . Tony Giordano, JanOne's chief scientific officer, "We are very fortunate to have had the foresight to initiate the manufacturing process this past February. Should we gain FDA approval for our Covid-19 study, we will be in a position to start patient trials immediately and still remain on track for our planned PAD Phase 2b trials to begin in early 2021."

The company expects to submit the investigational new drug (IND) for the treatment of Covid-19 vascular complications in the coming weeks and continues to advance plans to scale-up production of JAN101. The company has secured a partner for bottling and labeling, GMP batch production, including placebo batches. The company expects to deliver 250,000 doses within 30 days after start of manufacturing and have GMP batches of more than 20 million doses ready next year.

In various animal studies, JAN101 has demonstrated positive benefits that align with COVID-19 complications

Reduces kidney damage
Prevents tissue necrosis
Reduces thrombosis
Increases angiogenesis
The JAN101 COVID-19 Vascular Treatment Opportunity

As indicated in multiple human trials, our current sodium nitrate compound may be a successful treatment for the vascular complications experienced by COVID-19 patients

Shown to improve vascular function
Shown to reduce vascular complications such as thrombosis
Protects major organs from tissue damage due to poor blood flow
Inhibits inflammation, including mitigating the “cytokine storm”, a massive release of cytokine proteins that destroy endothelial cells (cells that protect the lining of vessel tissue)
Nitrite has proven to be well tolerated and safe
Peripheral Artery Disease Market Projected Be Valued At $52B By 2022

In the US alone, PAD affects nearly 12 million people, and if left untreated will lead to Critical Limb Ischemia with an annual cost of care estimated at $10 billion. 1 in every 20 adults over the age of 50 years, and 1 in every 4 adults over the age of 70 years are likely to develop PAD.

JAN's JAN101 is intended to address the 12 million Americans who suffer from PAD. In 2017, the global market for PAD was estimated at nearly $36.1 billion and is expected to grow at a compound annual growth rate ( CAGR ) of 7.6% to $52.0 billion by 2022

Growing number of patients suffering from peripheral artery disease across the globe and surge in population of ageing people across the European countries drive the growth of the global peripheral artery disease market.

Technical Analysis

We've done our very own chart analysis and see the potential for a big move from here!

JAN's share structure also seems attractive to those looking for a ticker with tremendous breakout potential!

Bullish Indicators:

Stock continues to run higher within a very bullish ascending channel , which remains perfectly respected.
20 moving average remains as support.
Stock has moved above VWAP
RSI is in bullish uptrend
Stochastic has bottomed and crossed bullishly.
The Bottom Line

JAN could be our next Nasdaq listed alert to run-up big.

The Company's razor thin float is a day traders dream come true.

JAN is in the midst of a major growth period, and has several bullish catalysts on the horizon.

Now may be the perfect time to take a closer look at JAN.

As always, we encourage you to do further research. Also, when you find yourself in a position to profit, it is often wise to do so.By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)

[ddbl_our_buck]

Dunno ~ I think it’s the shares everyone wants and there’s just not enough! $JAN ..gl bro

[kentstate12]

wow, did it ever! wITH SUCH LOW volume i wasn't sure how it would sustain this move. major news coming?

[ddbl_our_buck]

..and today and tomorrow and the next day $JAN

[Wrangler28]

what is going on with investor hub prices, Yahoo finance is at over $7

[Wrangler28]

Low float and money moving in will push this up today

[Principian]

Anyone else wondering how all these seasoned Medical Professionals are being compensated?

[Principian]

Well the Biggest "Red Flag" for Geotraq now under Pierre Parent as GM/CTO running the Show is there still is no FCC Certifications on file. Not even any filings requesting any "Waivers"

Neither are there any Certifications from any of the main Cellular Service Providers such as Verizon or AT&T.

This goes for that original bogus design under Gregg Sullivan and this new design that is advertised as using Sequans Chips.

They are way more than a day late and a dollar short to have a working product in the market. At this point they are more than 3 years without a single sale and a positive feedback of a satisfied customer.

Oh and then there is that worthless Patent. I find it funny there now is hardly any mention of having this "Grand Solution" that only Gregg Sullivan was Genius enough to invent.

[againstallodds]

The old Sullivan dinosaur stuff IMO

[Principian]

Maybe someone in Las Vegas should go see if they are still in that office.

One thing I noticed as part of the JAN/ARCI Balance Sheet they have a note on holding $200K worth of "Chips". I am wondering if this is Sequans Chips they may have bought or are they inflating the worthlessness of those Modules Sullivan kept trying to impress people like me with that actually never worked.

[againstallodds]

Probably will get paid in shares of a worthless other company and not is cash for Geotraq.

Big reduction in intangible assets expected. Monitoring of the financial rations required for the debt holders.

Yhis was written in the sky.

Me thinks Geotraq inoperant since mid april.

Let's see in the expected lawsuit proceeds, and how this will impact Jan.

[Principian]

They are in a pickle for sure. No way any entity would buy Geotraq and then there is the small problem of the inflated Intangible Assets and those Preferred Shares.

[againstallodds]

Looks like JAN will jettison GeoTraq IMO

[DJ Ponder]

ROFLMAO....at low life sullivan.

Greggy, Pizza not allowed in Court…

JuST A HEADS UP FOR YA !

The lil pompous ass.

[againstallodds]

Here's what's coming for Greggy: Court…

Pizza not allowed, and please dress properly in front of the judge…



BUSTED

[againstallodds]

Greggy, Pizza not allowed in Court…

JuST A HEADS UP FOR YA !

[DJ Ponder]

Gregg sullivan scumbag. I almost wish I would have bought stock just to see him squirm.
What a waste of human flesh.

[againstallodds]

What a financial burden Geotraq is!

What is the point of keeping it in the portfolios of companies ?

[Principian]

Shareholder Lawsuit in the works.

I have good information on a possible future Lawsuit that is upcoming. Any prior Geotraq Employees or Shareholders can reach out to me and I can get you in contact with the Law Firm that more than likely will be filing the case. The Firm is interested in shareholders that were allegedly ripped off by Gregg Sullivan and then he up and cancelled the shares then sold out to ARCI.

[Principian]

Geotraq also has not filed any of the Necessary FCC Requirements. That is the biggest impediment to them even selling a single module.

From experience, this process takes about 90 days and they have had Pierre Parent now as the GM for over a year. This is a major Red Flag. This has now been going on for 3 years as to not have completed the necessary Compliance Testing and Carrier Approvals. Till this is complete, there will be No Sales.

Only thing I have seen Geotraq do with Twitter or Facebook is they seem to just be promoting these possible use cases.

Back in the fall, I had a few of my engineers inquire on getting details and after a few technical question emails were exchanged they never responded.

From looking at the numbers, they are still buring thru about $100K a month and that is on top of the ~$1 Million Writeoff they are doing each quarter on the Intangible Assets related to Geotraq.